Nexalis Therapeutics (ASX:NX1) appointed Niv Dagan to succeed Sean Williams as non-executive chairman, effective Friday, according to a same-day filing with the Australian bourse.
Williams, who has served in the role since July 2021, is resigning to focus on other business commitments and family matters, per the filing.
Dagan is the founder and executive director of boutique investment firm Peak Asset Management, the clinical-stage drug development company said. He is also currently the non-executive chairman of Spenda (ASX:SPX).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.